1. Cancer Biology
  2. Chromosomes and Gene Expression

Co-regulation and function of FOXM1/RHNO1 bidirectional genes in cancer

  1. Carter J Barger
  2. Linda Chee
  3. Mustafa Albahrani
  4. Catalina Munoz-Trujillo
  5. Lidia Boghean
  6. Connor Branick
  7. Kunle Odunsi
  8. Ronny Drapkin
  9. Lee Zou
  10. Adam R Karpf  Is a corresponding author
  1. University of Nebraska Medical Cancer, United States
  2. University of Nebraska Medical Center, United States
  3. Roswell Park Comprehensive Cancer Center, United States
  4. University of Pennsylvania Perelman School of Medicine, United States
  5. Massachusetts General Hospital Cancer Center, Harvard Medical School, United States
  6. University of Nebraska Medical Center;, United States
https://doi.org/10.7554/eLife.55070
Share this article
Cite this article
  1. Carter J Barger
  2. Linda Chee
  3. Mustafa Albahrani
  4. Catalina Munoz-Trujillo
  5. Lidia Boghean
  6. Connor Branick
  7. Kunle Odunsi
  8. Ronny Drapkin
  9. Lee Zou
  10. Adam R Karpf
(2021)
Co-regulation and function of FOXM1/RHNO1 bidirectional genes in cancer
eLife 10:e55070.
https://doi.org/10.7554/eLife.55070
  2. Download BibTeX
  3. Download .RIS

Abstract

The FOXM1 transcription factor is an oncoprotein and a top biomarker of poor prognosis in human cancer. Overexpression and activation of FOXM1 is frequent in high-grade serous carcinoma (HGSC), the most common and lethal form of human ovarian cancer, and is linked to copy number gains at chromosome 12p13.33. We show that FOXM1 is co-amplified and co-expressed with RHNO1, a gene involved in the ATR-Chk1 signaling pathway that functions in the DNA replication stress (RS) response. We demonstrate that FOXM1 and RHNO1 are head-to-head (i.e. bidirectional) genes (BDG) regulated by a bidirectional promoter (BDP) (named F/R-BDP). FOXM1 and RHNO1 each promote oncogenic phenotypes in HGSC cells, including clonogenic growth, DNA homologous recombination repair (HR), and poly-ADP ribosylase (PARP) inhibitor resistance. FOXM1 and RHNO1 are one of the first examples of oncogenic BDG, and therapeutic targeting of FOXM1/RHNO1 BDG is a potential therapeutic approach for ovarian and other cancers.

Data availability

All data generated are found within the manuscript and supporting files. sc-RNA-seq data is deposited in GEO.

The following previously published data sets were used
    1. Ann-Marie Patch 1
    2. Elizabeth L Christie 2
    3. Dariush Etemadmoghadam 3
    4. Dale W Garsed 2
    5. Joshy George 4
    6. Sian Fereday 2
    7. Katia Nones 1
    8. Prue Cowin 2
    9. Kathryn Alsop 2
    10. Peter J Bailey 5
    11. Karin S Kassahn 6
    12. Felicity Newell 7
    13. Michael C J Quinn 1
    14. Stephen Kazakoff 1
    15. Kelly Quek 7
    16. Charlotte Wilhelm-Benartzi 8
    17. Ed Curry 8
    18. Huei San Leong 2
    19. Australian Ovarian Cancer Study Group; Anne Hamilton 9
    20. Linda Mileshkin 10
    21. George Au-Yeung 2
    22. Catherine Kennedy 11
    23. Jillian Hung 11
    24. Yoke-Eng Chiew 11
    25. Paul Harnett 12
    26. Michael Friedlander 13
    27. Michael Quinn 14
    28. Jan Pyman 14
    29. Stephen Cordner 15
    30. Patricia O'Brien 15
    31. Jodie Leditschke 15
    32. Greg Young 15
    33. Kate Strachan 15
    34. Paul Waring 16
    35. Walid Azar 2
    36. Chris Mitchell 2
    37. Nadia Traficante 2
    38. Joy Hendley 2
    39. Heather Thorne 2
    40. Mark Shackleton 10
    41. David K Miller 7
    42. Gisela Mir Arnau 2
    43. Richard W Tothill 10
    44. Timothy P Holloway 2
    45. Timothy Semple 2
    46. Ivon Harliwong 7
    47. Craig Nourse 7
    48. Ehsan Nourbakhsh 7
    49. Suzanne Manning 7
    50. Senel Idrisoglu 7
    51. Timothy J C Bruxner 7
    52. Angelika N Christ 7
    53. Barsha Poudel 7
    54. Oliver Holmes 1
    55. Matthew Anderson 7
    56. Conrad Leonard 1
    57. Andrew Lonie 17
    58. Nathan Hall 18
    59. Scott Wood 1
    60. Darrin F Taylor 7
    61. Qinying Xu 1
    62. J Lynn Fink 7
    63. Nick Waddell 7
    64. Ronny Drapkin 19
    65. Euan Stronach 8
    66. Hani Gabra 8
    67. Robert Brown 8
    68. Andrea Jewell 20
    69. Shivashankar H Nagaraj 7
    70. Emma Markham 7
    71. Peter J Wilson 7
    72. Jason Ellul 2
    73. Orla McNally 11
    74. Maria A Doyle 2
    75. Ravikiran Vedururu 2
    76. Collin Stewart 21
    77. Ernst Lengyel 20
    78. John V Pearson 1
    79. Nicola Waddell 1
    80. Anna deFazio 11
    81. Sean M Grimmond 5
    82. David D L Bowtell
    (2015) HGSC RNA-seq
    EGAD00001000877.
    https://ega-archive.org/

Article and author information

Author details

  1. Carter J Barger

    Eppley Institute, University of Nebraska Medical Cancer, Omaha, United States
    Competing interests
    The authors declare that no competing interests exist.

  2. Linda Chee

    Eppley Institute, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    The authors declare that no competing interests exist.

  3. Mustafa Albahrani

    Eppley Institute, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    The authors declare that no competing interests exist.

  4. Catalina Munoz-Trujillo

    Eppley Institute, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    The authors declare that no competing interests exist.

  5. Lidia Boghean

    Eppley Institute, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    The authors declare that no competing interests exist.

  6. Connor Branick

    Eppley Institute, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    The authors declare that no competing interests exist.

  7. Kunle Odunsi

    Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, United States
    Competing interests
    The authors declare that no competing interests exist.

  8. Ronny Drapkin

    University of Pennsylvania Perelman School of Medicine, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.

  9. Lee Zou

    Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, United States
    Competing interests
    The authors declare that no competing interests exist.

  10. Adam R Karpf

    Eppley Institute, University of Nebraska Medical Center;, Omaha, United States
    For correspondence
    adam.karpf@unmc.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0866-0666

Funding

National Institutes of Health (P30CA036727)

  • Adam R Karpf

Rivkin Center for Ovarian Cancer

  • Adam R Karpf

Fred & Pamela Pamela Buffett Cancer Center

  • Adam R Karpf

UNMC Fellowship

  • Carter J Barger

McKinsey Ovarian Cancer Research Fund

  • Adam R Karpf

UNMC Core Facility Users Grant

  • Adam R Karpf

National Institutes of Health (T32CA009476)

  • Carter J Barger

National Institutes of Health (F99CA212470)

  • Carter J Barger

National Institutes of Health (P50CA228991)

  • Ronny Drapkin

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2021, Barger et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,506
    views
  • 341
    downloads
  • 21
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Carter J Barger
  2. Linda Chee
  3. Mustafa Albahrani
  4. Catalina Munoz-Trujillo
  5. Lidia Boghean
  6. Connor Branick
  7. Kunle Odunsi
  8. Ronny Drapkin
  9. Lee Zou
  10. Adam R Karpf
(2021)
Co-regulation and function of FOXM1/RHNO1 bidirectional genes in cancer
eLife 10:e55070.
https://doi.org/10.7554/eLife.55070

Share this article

https://doi.org/10.7554/eLife.55070

Categories and tags

Research organism

Further reading

    1. Cancer Biology

    Non-destructive in situ monitoring of structural changes of 3D tumor spheroids during the formation, migration, and fusion process

    Ke Ning, Yuanyuan Xie ... Ling Yu
    Research Article

    For traditional laboratory microscopy observation, the multi-dimensional, real-time, in situ observation of three-dimensional (3D) tumor spheroids has always been the pain point in cell spheroid observation. In this study, we designed a side-view observation petri dish/device that reflects light, enabling in situ observation of the 3D morphology of cell spheroids using conventional inverted laboratory microscopes. We used a 3D-printed handle and frame to support a first-surface mirror, positioning the device within a cell culture petri dish to image cell spheroid samples. The imaging conditions, such as the distance between the mirror and the 3D spheroids, the light source, and the impact of the culture medium, were systematically studied to validate the in situ side-view observation. The results proved that placing the surface mirror adjacent to the spheroids enables non-destructive in situ real-time tracking of tumor spheroid formation, migration, and fusion dynamics. The correlation between spheroid thickness and dark core appearance under light microscopy and the therapeutic effects of chemotherapy doxorubicin and natural killer cells on spheroids’ 3D structure was investigated.

    1. Cancer Biology

    NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model

    Ismail M Meraz, Mourad Majidi ... Jack A Roth
    Research Article

    Expression of NPRL2/TUSC4, a tumor-suppressor gene, is reduced in many cancers including NSCLC. Restoration of NPRL2 induces DNA damage, apoptosis, and cell-cycle arrest. We investigated NPRL2 antitumor immune responses in aPD1R/KRAS/STK11mt NSCLC in humanized-mice. Humanized-mice were generated by transplanting fresh human cord blood-derived CD34 stem cells into sub-lethally irradiated NSG mice. Lung-metastases were developed from KRAS/STK11mt/aPD1R A549 cells and treated with NPRL2 w/wo pembrolizumab. NPRL2-treatment reduced lung metastases significantly, whereas pembrolizumab was ineffective. Antitumor effect was greater in humanized than non-humanized-mice. NPRL2 + pembrolizumab was not synergistic in KRAS/STK11mt/aPD1R tumors but was synergistic in KRASwt/aPD1S H1299. NPRL2 also showed a significant antitumor effect on KRASmt/aPD1R LLC2 syngeneic-tumors. The antitumor effect was correlated with increased infiltration of human cytotoxic-T, HLA-DR+DC, CD11c+DC, and downregulation of myeloid and regulatory-T cells in TME. Antitumor effect was abolished upon in-vivo depletion of CD8-T, macrophages, and CD4-T cells whereas remained unaffected upon NK-cell depletion. A distinctive protein-expression profile was found after NPRL2 treatment. IFNγ, CD8b, and TBX21 associated with T-cell functions were significantly increased, whereas FOXP3, TGFB1/B2, and IL-10RA were strongly inhibited by NPRL2. A list of T-cell co-inhibitory molecules was also downregulated. Restoration of NPRL2 exhibited significantly slower tumor growth in humanized-mice, which was associated with increased presence of human cytotoxic-T, and DC and decreased percentage of Treg, MDSC, and TAM in TME. NPRL2-stable cells showed a substantial increase in colony-formation inhibition and heightened sensitivity to carboplatin. Stable-expression of NPRL2 resulted in the downregulation of MAPK and AKT-mTOR signaling. Taken-together, NPRL2 gene-therapy induces antitumor activity on KRAS/STK11mt/aPD1R tumors through DC-mediated antigen-presentation and cytotoxic immune-cell activation.

    1. Biochemistry and Chemical Biology
    2. Cancer Biology

    Synergistic effect of inhibiting CHK2 and DNA replication on cancer cell growth

    Flavie Coquel, Sing-Zong Ho ... Philippe Pasero
    Research Article

    Cancer cells display high levels of oncogene-induced replication stress (RS) and rely on DNA damage checkpoint for viability. This feature is exploited by cancer therapies to either increase RS to unbearable levels or inhibit checkpoint kinases involved in the DNA damage response. Thus far, treatments that combine these two strategies have shown promise but also have severe adverse effects. To identify novel, better-tolerated anticancer combinations, we screened a collection of plant extracts and found two natural compounds from the plant, Psoralea corylifolia, that synergistically inhibit cancer cell proliferation. Bakuchiol inhibited DNA replication and activated the checkpoint kinase CHK1 by targeting DNA polymerases. Isobavachalcone interfered with DNA double-strand break repair by inhibiting the checkpoint kinase CHK2 and DNA end resection. The combination of bakuchiol and isobavachalcone synergistically inhibited cancer cell proliferation in vitro. Importantly, it also prevented tumor development in xenografted NOD/SCID mice. The synergistic effect of inhibiting DNA replication and CHK2 signaling identifies a vulnerability of cancer cells that might be exploited by using clinically approved inhibitors in novel combination therapies.